Bexobrutideg (NX-5948) is an investigational new drug that is being evaluated by Nurix Therapeutics for the treatment of relapsed and refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.